Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR, Sumitomo Sign Copromotion Pact for Izcargo in Japan
April 7, 2023
- Japan Pharma Sales Up 1.3% in FY2022: Encise
April 7, 2023
- Kissei’s ITP Med Tavalisse Now Available in Japan
April 7, 2023
- Major Renovation at Eisai’s Tsukuba Lab Completed
April 7, 2023
- Kowa Kicks Off Another PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
April 7, 2023
- MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
April 6, 2023
- Macrocyclic Peptide Hits Milestone in Joint R&D: PeptiDream/Bayer
April 6, 2023
- Avastin Biosimilar Grabs Ovarian Cancer Nod: Nippon Kayaku/Celltrion
April 6, 2023
- Sumitomo to Combine US Subsidiaries as It Looks towards Post-Latuda Era
April 5, 2023
- Lecanemab Use at MCI Stage Might Have Larger Impact on Delaying AD Progression: Eisai
April 5, 2023
- Padcev/Keytruda Combo Wins US Accelerated Nod for First-Line Bladder Cancer: Astellas
April 5, 2023
- Xocova Nabs Fast-Track Tag in US: Shionogi
April 5, 2023
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Insmed Taps Ex-Gilead Director Makoto Nakamura as New Japan Chief
April 4, 2023
- Yoshihiro Toyohara to Lead Teva Takeda from June
April 4, 2023
- Eisai to Offer Tazverik for NCC’s Patient-Proposed Study
April 4, 2023
- 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
- 5 Otsuka Execs Earn 100 Million-Plus Pay in 2022: Securities Filing
April 4, 2023
- Chugai’s Annual Pay Tops 12 Million Yen for 1st Time: Securities Report
April 4, 2023
- Sanofi Seeks Dupixent Label Expansion into CSU in Japan
April 3, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…